All In Biotech

NDA 210238 · Akarx INC

Doptelet

Avatrombopag Maleate · Oral

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

May 21, 2018

Approved uses

3

Original approval plus efficacy supplements

Registered trials

56

16 Phase 3, 5 recruiting

FAERS reports

2,368

839 serious, 138 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 13, 2025.

DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1.1 ) Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. ( 1.2 ) Thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment ( 1.3 ) 1.1 Treatment of Thrombocytopenia in Patients with Chronic Liver Disease (CLD) DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. 1.2 Treatment of Thrombocytopenia in Adult Patients with Chronic Immune Thrombocytopenia (ITP) DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. 1.3 Treatment of Thrombocytopenia in Pediatric Patients 1 Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP) DOPTELET is indicated for the treatment of thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Mechanism: Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 24, 2025 Supplement 10 · Efficacy OrphanLetterLabel
  • Jun 26, 2019 Supplement 1 · Efficacy OrphanLetterLabel
  • May 21, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • DOPTELET · AVATROMBOPAG MALEATE EQ 20MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Avatrombopag" as an intervention, any sponsor and status, largest first.

All 56 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • platelet count decreased420
  • drug ineffective333
  • headache252
  • platelet count increased217
  • fatigue189
  • nausea123
  • product dose omission issue118
  • platelet count abnormal117
  • off label use116
  • death95
  • diarrhoea89
  • inappropriate schedule of product administration82

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20151
201864
2019106
2020269
2021265
2022237
2023282
2024315
2025375
2026453

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Doptelet (Avatrombopag Maleate)

2024 spending

$160M

Beneficiaries

2,329

11,800 claims

Per beneficiary

$68,560

$406.38 per unit

View as table
YearSpending
2020$18,925,776
2021$34,706,105
2022$60,589,108
2023$96,044,175
2024$159,677,266

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 38 on PubMed

Sponsor: Akarx INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.